Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 32

1.

A non-cell autonomous mouse model of CNS haemangioblastoma mediated by mutant KRAS.

Bao L, Al-Assar O, Drynan LF, Arends MJ, Tyers P, Barker RA, Rabbitts TH.

Sci Rep. 2017 Mar 21;7:44899. doi: 10.1038/srep44899.

2.

Modelling of a targeted nanotherapeutic 'stroma' to deliver the cytokine LIF, or XAV939, a potent inhibitor of Wnt-β-catenin signalling, for use in human fetal dopaminergic grafts in Parkinson's disease.

Zhao JW, Dyson SC, Kriegel C, Tyers P, He X, Fahmy TM, Metcalfe SM, Barker RA.

Dis Model Mech. 2014 Oct;7(10):1193-203. doi: 10.1242/dmm.015859. Epub 2014 Aug 1.

3.

Dopaminergic manipulations and its effects on neurogenesis and motor function in a transgenic mouse model of Huntington's disease.

Choi ML, Begeti F, Oh JH, Lee SY, O'Keeffe GC, Clelland CD, Tyers P, Cho ZH, Kim YB, Barker RA.

Neurobiol Dis. 2014 Jun;66:19-27. doi: 10.1016/j.nbd.2014.02.004. Epub 2014 Feb 19.

PMID:
24561069
4.

The long-term safety and efficacy of bilateral transplantation of human fetal striatal tissue in patients with mild to moderate Huntington's disease.

Barker RA, Mason SL, Harrower TP, Swain RA, Ho AK, Sahakian BJ, Mathur R, Elneil S, Thornton S, Hurrelbrink C, Armstrong RJ, Tyers P, Smith E, Carpenter A, Piccini P, Tai YF, Brooks DJ, Pavese N, Watts C, Pickard JD, Rosser AE, Dunnett SB; NEST-UK collaboration.

J Neurol Neurosurg Psychiatry. 2013 Jun;84(6):657-65. doi: 10.1136/jnnp-2012-302441. Epub 2013 Jan 23.

5.

A novel neuroprotective therapy for Parkinson's disease using a viral noncoding RNA that protects mitochondrial complex I activity.

Kuan WL, Poole E, Fletcher M, Karniely S, Tyers P, Wills M, Barker RA, Sinclair JH.

J Exp Med. 2012 Jan 16;209(1):1-10. doi: 10.1084/jem.20111126. Epub 2011 Dec 19.

6.

Clusterin secreted by astrocytes enhances neuronal differentiation from human neural precursor cells.

Cordero-Llana O, Scott SA, Maslen SL, Anderson JM, Boyle J, Chowhdury RR, Tyers P, Barker RA, Kelly CM, Rosser AE, Stephens E, Chandran S, Caldwell MA.

Cell Death Differ. 2011 May;18(5):907-13. doi: 10.1038/cdd.2010.169. Epub 2011 Jan 7.

7.

Neuropeptide Y modifies the disease course in the R6/2 transgenic model of Huntington's disease.

Decressac M, Wright B, Tyers P, Gaillard A, Barker RA.

Exp Neurol. 2010 Nov;226(1):24-32. doi: 10.1016/j.expneurol.2010.07.022. Epub 2010 Jul 29.

PMID:
20673761
8.

Adult neurogenesis is unaffected by a functional knock-out of MHC class I in mice.

Laguna Goya R, Tyers P, Barker RA.

Neuroreport. 2010 Mar 31;21(5):349-53. doi: 10.1097/WNR.0b013e3283377463.

PMID:
20147861
9.

Exogenous neuropeptide Y promotes in vivo hippocampal neurogenesis.

Decressac M, Wright B, David B, Tyers P, Jaber M, Barker RA, Gaillard A.

Hippocampus. 2011 Mar;21(3):233-8. doi: 10.1002/hipo.20765.

PMID:
20095007
10.

A functional role for adult hippocampal neurogenesis in spatial pattern separation.

Clelland CD, Choi M, Romberg C, Clemenson GD Jr, Fragniere A, Tyers P, Jessberger S, Saksida LM, Barker RA, Gage FH, Bussey TJ.

Science. 2009 Jul 10;325(5937):210-3. doi: 10.1126/science.1173215.

11.

Dopamine-induced proliferation of adult neural precursor cells in the mammalian subventricular zone is mediated through EGF.

O'Keeffe GC, Tyers P, Aarsland D, Dalley JW, Barker RA, Caldwell MA.

Proc Natl Acad Sci U S A. 2009 May 26;106(21):8754-9. doi: 10.1073/pnas.0803955106. Epub 2009 May 11.

12.

Graft outcomes influenced by co-expression of Pax7 in graft and host tissue.

Thomas M, Tyers P, Lazic SE, Caldwell MA, Barker RA, Beazley L, Ziman M.

J Anat. 2009 Mar;214(3):396-405. doi: 10.1111/j.1469-7580.2009.01049.x. Erratum in: J Anat. 2009 Aug;215(2):225. Caldwell, Maeve A [added].

13.

Induction of A9 dopaminergic neurons from neural stem cells improves motor function in an animal model of Parkinson's disease.

O'Keeffe FE, Scott SA, Tyers P, O'Keeffe GW, Dalley JW, Zufferey R, Caldwell MA.

Brain. 2008 Mar;131(Pt 3):630-41. doi: 10.1093/brain/awm340. Epub 2008 Jan 17.

PMID:
18202103
14.

The search for a curative cell therapy in Parkinson's disease.

Laguna Goya R, Tyers P, Barker RA.

J Neurol Sci. 2008 Feb 15;265(1-2):32-42. Epub 2007 Oct 23. Review.

PMID:
17936303
15.

The effect of truncated human alpha-synuclein (1-120) on dopaminergic cells in a transgenic mouse model of Parkinson's disease.

Michell AW, Tofaris GK, Gossage H, Tyers P, Spillantini MG, Barker RA.

Cell Transplant. 2007;16(5):461-74.

PMID:
17708336
16.
17.

EGF and FGF-2 responsiveness of rat and mouse neural precursors derived from the embryonic CNS.

Kelly CM, Tyers P, Borg MT, Svendsen CN, Dunnett SB, Rosser AE.

Brain Res Bull. 2005 Dec 15;68(1-2):83-94. Epub 2005 Sep 21.

PMID:
16325008
18.

Long-term survival and integration of porcine expanded neural precursor cell grafts in a rat model of Parkinson's disease.

Harrower TP, Tyers P, Hooks Y, Barker RA.

Exp Neurol. 2006 Jan;197(1):56-69. Epub 2005 Oct 24.

PMID:
16246328
19.

The survival of neural precursor cell grafts is influenced by in vitro expansion.

Zietlow R, Pekarik V, Armstrong RJ, Tyers P, Dunnett SB, Rosser AE.

J Anat. 2005 Sep;207(3):227-40. Review.

20.
21.

GABAergic immunoreactivity is predominant in neurons derived from expanded human neural precursor cells in vitro.

Jain M, Armstrong RJ, Tyers P, Barker RA, Rosser AE.

Exp Neurol. 2003 Jul;182(1):113-23.

PMID:
12821381
22.

Transplantation of expanded neural precursor cells from the developing pig ventral mesencephalon in a rat model of Parkinson's disease.

Armstrong RJ, Tyers P, Jain M, Richards A, Dunnett SB, Rosser AE, Barker RA.

Exp Brain Res. 2003 Jul;151(2):204-17. Epub 2003 Jun 3.

PMID:
12783147
23.

The potential for circuit reconstruction by expanded neural precursor cells explored through porcine xenografts in a rat model of Parkinson's disease.

Armstrong RJ, Hurelbrink CB, Tyers P, Ratcliffe EL, Richards A, Dunnett SB, Rosser AE, Barker RA.

Exp Neurol. 2002 May;175(1):98-111.

PMID:
12009763
24.

Porcine neural xenografts in the immunocompetent rat: immune response following grafting of expanded neural precursor cells.

Armstrong RJ, Harrower TP, Hurelbrink CB, McLaughin M, Ratcliffe EL, Tyers P, Richards A, Dunnett SB, Rosser AE, Barker RA.

Neuroscience. 2001;106(1):201-16.

PMID:
11564430
26.

Long-term survival of human central nervous system progenitor cells transplanted into a rat model of Parkinson's disease.

Svendsen CN, Caldwell MA, Shen J, ter Borg MG, Rosser AE, Tyers P, Karmiol S, Dunnett SB.

Exp Neurol. 1997 Nov;148(1):135-46.

PMID:
9398456
27.

Characterisation of the immune response in a neural xenograft rejection paradigm.

Litchfield TM, Whiteley SJ, Yee KT, Tyers P, Usherwood EJ, Nash AA, Lund RD.

J Neuroimmunol. 1997 Mar;73(1-2):135-44.

PMID:
9058769
28.

Co-expression of MAP-2 and GFAP in cells developing from rat EGF responsive precursor cells.

Rosser AE, Tyers P, ter Borg M, Dunnett SB, Svendsen CN.

Brain Res Dev Brain Res. 1997 Feb 20;98(2):291-5.

PMID:
9051273
29.
30.

Transfection with hsp70i protects rat dorsal root ganglia neurones and glia from heat stress.

Uney JB, Staley K, Tyers P, Sofroniew MV, Kew JN.

Gene Ther. 1994;1 Suppl 1:S65.

PMID:
8542411
31.
32.

Supplemental Content

Support Center